For this reason, the SWAP design, and SWAP-RAP12x2 in particular, represents a favourable transgene candidate for lentiviral gene therapy for Hunter syndrome, as well as for approaches involving IGF2-based therapeutics where peak plasma levels strongly exceed those achieved by HSPC‐LVGT (e.g., ERT). Here, IGF2 is linked to mucopolysaccharidosis type 2.